X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used to fund the clinical advancement of company lead product BETR-001 (2-Bromo-Lysergic Acid Diethylamide), which is being evaluated for the treatment of major depressive disorder and anxiety disorder.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 03, 2024
Details:
The net proceeds will advance the development its lead compound, BETR-001, a proprietary 2-bromo-LSD, a non-hallucinogenic derivative of lysergic acid diethylamide (LSD), in developement for the treatment of major depressive disorder, anxiety disorder and neuropathic pain.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
BETR-001 (2-bromo-LSD) is a non-hallucinogenic and noncontrolled LSD derivative in development for treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
BETR-001 (2-bromo-LSD) is a non-hallucinogenic and noncontrolled LSD derivative in development for treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
NYPRG-101, also referred to in the literature as BOL-148 (2-bromo-d-lysergic acid diethylamide), is a non-hallucinogenic analog of LSD, differing by only one atom. It is currently in phase 1 clinical trial for migraine and cluster headache.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Neurology Product Name: BOL-148
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
BETR-001 (2-bromolysergic acid diethylamide), which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self administered.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Negev Capital
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 07, 2022
Details:
BETR-001 (2-bromolysergic acid diethylamide) is a second-generation LSD derivative molecule that does not cause hallucinations. The synthesis of BETR-001 is via non-controlled substance synthetic route, and therefore not subject to controlled substance regulatory restrictions.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
BETR-001 (2-Bromolysergic Acid Diethylamide), is a second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Carleton University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2022
Details:
NYPRG-101 (2-bromo-D-lysergic acid diethylamide), referred as BOL-148, is a non-hallucinogenic analog of LSD. Results from IND-enabling pre-clinical toxicology work as well as research conducted with human subjects, indicate a positive safety profile for NYPRG-101.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Neurology Product Name: NYPRG-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide derivative molecule. BETR-001 is a uniquely positioned LSD derivative with the potential to be as effective as LSD in various neuropsychiatric and neurological disorders without the burden of being hallucinogenic.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The study demonstrated that treatment of rat embryonic cortical neurons with BETR-001 increases structural complexity of neurons (dendrite growth and complexity) and therefore, provides evidence of neural plasticity activity of BETR-001.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Key PK data points from the mouse study demonstrated that BETR-001 appeared quickly (10 minutes post dose) in the plasma and brain of mice following a single dose and remained detectable up to 8 hours post dose.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nucro-Technics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
The first set of positive data for TD-0148A (2-Bromo-Lysergic Acid Diethylamide) showing anti-depressant properties by significantly reversing both depressive-like behaviors in the mice.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
TD-0148A is a second-generation Lysergic Acid Diethylamide derivative molecule that company believes will mimic the therapeutic potential of LSD without causing psychedelic effects in treatment of psychiatric and neurological disorders.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: UC San Diego School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
TD-0148A is a non-hallucinogenic second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders such as depression, post-traumatic stress disorder (“PTSD”), and migraines.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
TD-0148A is a second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing undesirable psychoactive dissociative side effects, such as hallucinations.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
As part of the research, Dr. McCorvy’s team will work with BetterLife to delineate TD-0148A’s signaling profile against various G protein coupled receptor (“GPCR”) relevant in neuro-psychiatry.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medical College of Wisconsin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 09, 2021
Details:
TD-0148A is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Carleton University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2021
Details:
The IP consists of a combination of BOL-148, which has demonstrated potential for treating cluster headaches in a human study, and a neuroprotectant that is believed to act in unison with BOL-148.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide,Neuroprotective Agent
Therapeutic Area: Neurology Product Name: BOL-148
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: HAVN Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 02, 2021
Details:
The IP consists of a combination of BOL-148, which has demonstrated potential for treating cluster headaches in a human study, and a neuroprotectant that is believed to act in unison with BOL-148.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide,Neuroprotective Agent
Therapeutic Area: Neurology Product Name: BOL-148
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: HAVN Life
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 17, 2021
Details:
TD-0148A is a second-generation lysergic acid diethylamide ("LSD") derivative that BetterLife believes will mimic the therapeutic potential of LSD without producing hallucinogenic effects or other psychoactive side-effects.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
